Clinical trial · no report yet · Phase not applicable
SARON
Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer
- NCT02417662 ↗
- Active not recruiting
- University College, London
- 30 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 27 | |
| Podcasts | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer. A Randomised Phase II Trial
- Phase
- Phase not applicable
- Status
- Active not recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Radical Radiotherapy (Conventional RT and SABR); Non-investigational SACT
- Arms
- Systemic Anti-Cancer Therapy (SACT) alone · Active comparator
- SACT + Radical Radiotherapy (Conventional RT and SABR) · Experimental
- Enrollment
- 140
- Primary outcomes
- Overall Survival
- Sponsor
- University College, London with Cancer Research UK
- Start
- Aug 19, 2016
- Primary completion
- Sep 2026 (estimated)
- Results posted
- No
- Registry record
- NCT02417662 · updated May 6, 2026
Publications
linked from the registry- Conibear J, Chia B, Ngai Y, Bates AT, Counsell N, Patel R, Eaton D, Faivre-Finn C, Fenwick J, Forster M, Hanna GG, Harden S, Mayles P, Moinuddin S, Landau D. Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer. BMJ Open. 2018 Apr 17;8(4):e020690. doi: 10.1136/bmjopen-2017-020690. PubMed 29666135